Shannon M. Matulis

Emory University — United States

Medicine · Health Sciences

19h-index1.8kcitations157works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(111), Protein Degradation and Inhibitors(74), Peptidase Inhibition and Analysis(28), Chemokine receptors and signaling(20), Cancer, Lipids, and Metabolism(19)

Publications157 total

Table S2 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
2026Open Access
Table S4 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
2026Open Access
Table S1 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
2026Open Access
Table S5 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
2026Open Access
Supplementary Figures S1-S6 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
2026Open Access
Table S3 from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
2026Open Access
Data from ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
2026Open Access
Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH)
Blood·2026
Inhibition of NSD2 in t(4;14) myeloma induces changes in mitochondrial priming
Blood·2025
NSD2 expression remodels DNA methylation, creating a targetable epigenetic dependency in t(4;14) multiple myeloma
Blood·2025
ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3
Blood Cancer Discovery·2025Open Access
A Single-Cell Coding and Noncoding Transcriptomic Atlas Reveals ncRNA-Driven Remodeling of the Bone Marrow Microenvironment in Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025
Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis
Blood·2024· 5 citedOpen Access
Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax
Blood·2024Open Access
Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2
Blood·2024
P-234 Autocrine IL6 Signaling in Stromal Cells in Multiple Myeloma Influences the Bone Marrow Microenvironment
Clinical Lymphoma Myeloma & Leukemia·2024
Figure S9 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
Table S6 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
Figure S13 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
FIGURE 5 from Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Lawrence Boise(46), Sagar Lonial(28), Vikas A. Gupta(27), Ajay K. Nooka(25), Jonathan L. Kaufman(17), Benjamin G. Barwick(11), Mala Shanmugam(8), David L. Jaye(8), Jonathan J. Keats(8), Craig C. Hofmeister(8), Leonard T. Heffner(6), Joel Johansson(6), Yong Cai(6), Dennis Juarez(5), Roberta Buono(5), Madeleine Duong(5), Jacob Yudiono(5), Madhuri Paul(5), Sharmila Mallya(5), Grace Diep(5)